References
- International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled clinical trials of drugs in migraine, 1st ed. Cephalalgia 1991;11:1–12
- Ryan R, Géraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(Suppl):S84–92
- Géraud G, Spierings E, Keywood C. Tolerability and safety of frovatriptan with short and long term use for treatment of migraine and in comparison with sumatriptan. Headache 2002;42(Suppl):S93–99
- Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range finding studies with frovatriptan in the acute treatment of migraine. Headache 2002;42(Suppl):S74–83
- Géraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical pharmacological and pharmacokinetic properties of triptans. Headache 2003;43:376–88
- Cady R, Keywood C. Frovatriptan preliminary efficacy in early treatment of migraine attacks. Cephalalgia 2001;21:426–27
- Hu XH, Markson LE Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–8
- Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the medical outcomes study instrument. Headache 1993;33:351–8
- Stang P, Cady RK, Batenhorst A, Hoffman L. Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:231–44
- Cady RK, Sheftell F, Lipton RB, et al. Effects of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. Clinical Therapeutics 2000;22:1035–48
- Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabling migraine sufferers: results of the Spectrum Study. Headache 2000;40:792–7
- Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28–31
- Klapper J, Charlesworth B, Soisson T, Poole Jergensen A. Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain free response rates and prevents progression to more severe migraine in patients with significant migraine-related disability. Headache 2002;42: 395
- Halpern MT, Lipton RB, Cady RK, et al. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002;42:984–99